JPMorgan raised the firm’s price target on Mereo BioPharma (MREO) to $8 from $7 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MREO:
- Mereo Biopharma Group Plc: Strategic Advancements and Promising Developments Justify Buy Rating
- Promising Future for Mereo Biopharma: Buy Rating Backed by Positive Trial Prospects and Strong Market Position
- Mereo BioPharma Reports Increased Losses Amid Strategic Focus
- Positive Outlook for Mereo Biopharma Group Plc: Buy Rating Supported by Strong Financial Position and Promising Study Results
- Mereo BioPharma reports Q2 EPS (2c), consensus (1c)